Dear members and other friends of NSGO,

We are living in interesting times as medical professionals: discoveries in molecular genetics, dating to the 1990s, are finally being transformed into clinical practice, as we are getting results from well-designed studies on the use of new targeted drugs for various gynecological cancers. At the same time, the surgical techniques are getting more sophisticated. All this means, that it is of utmost importance, that we keep us updated on the new developments in the field, and most importantly, that our Nordic community, represented by NSGO, is actively participating in this research activity. We are on a very good track with this: NSGO-CTU is the sponsor and initiator of several new and ongoing trials, and the Surgery and Radiotherapy Groups are working actively.

The NSGO Board had its Strategic meeting mid-September in Copenhagen. We finalized the program for our Annual Meeting 2020 (Oslo 5-6 March). The themes for this annual meeting are Prevention and Heredity (= how has our knowledge of genetics impacted the treatment of gynecological cancers). With these themes we were able to create a very update program with interesting speakers. The program will be available on the NSGO website in December, and of course, we would like you all to save the date already in your calendars, and we wish to see you in Oslo!

The board also discussed several other issues, such as accreditations, quality control and our (now eternal, it seems) Membership fee problem, for which we are trying to find a solution which would work. NSGO also decided to open a twitter account for fast information delivery, this was tried a few years ago, but then we were maybe a little ahead of our time. A very important initiative came from Isa Niemann from Denmark, and the Board decided to take immediate action on this. This initiative was to adopt climate–friendly politics in NSGO. The first visible change to the members is that the 2020 Annual meeting will be a paper-free meeting, so no binders will be distributed there.

Finally, I would like to welcome our new Newsletter Editor Olesya Solheim from Norway, and give Gabriel Lindahl from Sweden a huge thanks for being our Newsletter Editor in the previous years! Wishing you all an enjoyable fall.

Annika Auranen, President of NSGO

NSGO Annual Meeting
March 4–6, 2020
Prevention and heredity in cancer
Radisson Blu Airport Hotel, Oslo Gardermoen
Dear members and collaborators of NSGO

NSGO-CTU had another busy and successful year. We have been busy in cleaning data and producing results of our trials. AVANOVA2, a NSGO-CTU sponsored trial, was accepted as oral presentation at ASCO selected as “Best of ASCO”. These results are published in the Lancet Oncology. The overall survival is planned to be presented in the second half of 2020. We believe that this is the beginning of minimizing the need for conventional chemotherapy and we are to start the phase 3 validation of the concept: chemotherapy-free treatment.

In 2019 we were able to finish recruitment of some of the important NSGO led trials; ENGOT-EN2, answering the key question: whether adjuvant chemotherapy is required in high or intermediate-high risk early stage endometrial cancer or not,

ENGOT-EN3 / NSGO-PALEO: Globally first randomized trial to test role of CDK4/6 inhibitors in endometrial cancer and

ENGOT-EN1 / NSGO-FANDANGO: A trial testing the role of anti-angiogenic therapy in endometrial cancer.

We are cleaning the data and are waiting for maturity for all above mentioned trials.

We have also concluded recruitment in cohort A of NSGO-Umbrella trial, and translational research projects are being planned. Furthermore, we have successfully initiated some of the important trials:

ENGOT-EN7 / NSGO-RUBY is the global phase 3 trial (EU, Canada & US) of immune-checkpoint inhibitors in endometrial cancer.

NSGO-CTU is proud to have global lead of this important study.

Our ongoing and planned trials are covering some of the most important questions in all gynae diseases and multiple surgical trials are to begin.

An important addition to NSGO-CTU is Estonia & Lithuania joining us and my heartiest welcome to the colleagues from these two countries.

All this success is due to the hard work of our office staff and due to your close collaboration and I thank all of you. NSGO-CTU is globally one of the major clinical trial organization and we are proud of it.

Thank you!

Mansoor Mirza, Medical Director.
The NSGO Surgery Group

First, I want to thank you all for your attendance at the annual meeting in Copenhagen!

The main activities in the surgery group are planned to coincide with the NSGO annual meeting, and hopefully, you will all participate in the future meeting in Oslo in 2020!

Fourteen NSGO members participated in the surgery group meeting in Copenhagen.

Unfortunately, the meeting was announced as a ‘closed meeting’ and more participants in the annual meeting didn’t know that the meeting was open for everybody, except the sponsors.

Future meetings should be announced without the comment ‘closed meeting’.

From the surgery group meeting in Copenhagen:

ERAS SURVEY - A NSGO-MANGO international survey in collaboration with AGO Austria. More of the representatives from the Nordic centers expressed their interest in a future collaboration regarding the perioperative care.

NSGO president Annika Auranen joined the meeting and Annika offered to support a workshop for the NSGO members to discuss and elaborate a Nordic collaboration concerning this important topic. Kristina Lindemann (Oslo University Hospital, Norway) and Elisa Piovano (Ospedale Regina Montis Regalis, Mondovì, Italy)

Minimal invasive surgery in cervical cancer The New England Journal of Medicine publication concerning the Laparoscopic Approach to Cervical Cancer (LACC) was discussed at the annual meeting.

In contrast to the LACC publication there are no increased recurrence and mortality in Sweden and Denmark. Henrik Falconer concluded that LACC does not reflect current practice in the Nordic countries and in the LACC-trial a low internal validity can be suspected. The practice in the Nordic countries differs dramatically compared to most systems worldwide concerning centralization, high-volume centers, high-volume surgeons, high volume oncologists, accreditation, standardized work-up, and standardized adjuvant treatment. However, it can be questioned whether real world data beats RCTs. Therefore, we need a new RCT and Henrik Falconer presented the RACC trial – Robot-assisted Approach to Cervical Cancer. The trial is expected to be launched in 2019 and 15 sites have expressed their interest. If you are interested in this study, please contact Henrik Falconer, Stockholm. We have a unique opportunity to collaborate within the Nordic countries!

A clinical NSGO database for research with focus on benchmarking and quality control

Tine Henrichsen Schnack pointed out that the mission of the Nordic Gynecological Cancer Cohort group under NSGO is:

• To establish a Nordic cohort of gynecological cancer patients

• To build a data platform, which can house and update the Nordic gynecological cancer cohort within NSGO

• Provide data for planning of prospective studies and randomized clinical trials

• Provide data on rare gynecological malignancies

• Provide data for studies, which examine the generalizability of results obtained from highly selected patients in randomized clinical trials.

• Provide data for benchmarking projects
NSGO president Annika Auranen offered to support a workshop for the NSGO members to discuss the legal aspects, the structure of the database, and which variables to include in the database.

A joint meeting with the ERAS group is planned in the spring 2020 when Ane Gerda is the chair of the surgery group.

I have been the chair of the surgery group for four years and I think it’s time to handing over the baton to Ane Gerda Zahl Eriksson, Oslo. Therefore, if you have any proposals for the agenda of the meeting in Oslo, please let Ane Gerda know in due time.

I want to welcome Ane Gerda as the new chair of the NSGO surgery group and, I wish you good luck in your collaboration with all these excellent colleagues!

We are looking forward seeing you all in Oslo!

November the 4th 2019

Jan Blaakaer, Odense

A Final Word from the Editor

Dear NSGO members and colleagues,

I am very proud to have been chosen as the new NSGO Newsletter Editor. I will do my utmost to carry forward the good work that my predecessor Gabriel has done for our Society.

I am sure that our investigator meeting in Copenhagen was interesting and useful. Since my main research interest is in rare tumour I am happy that we finally succeed in establishing a project on the study of low grade ovarian cancer.

I will use this opportunity to invite you all to the NSGO annual meeting which will be devoted the interesting topic of prevention and heredity in cancer. The meeting will take place in a nice Radisson Blu Airport hotel close to Oslo Airport Gardermoen in the period 4-6 March. This is not far from Oslo city for those who want to make a brief visit there.

I would also like to invite you to a very exiting pre-course “NSGO Basic Colposcopy Course” organised by my amazing colleague, Ameli Tropé. You can sign up to the pre-course by sending email to farnas@ous-hf.no

Finally, with the snow falling abundantly outside our windows and the temperature dropping far below zero, I will wish you a Merry Christmas and a Happy New Year.

Dear NSGO members and friends,

Well met in Oslo 2020!

Olesya Solheim, Oslo